Advertisement

Pluripotent Cell-Derived Glial Precursor Cells for the Delivery of Therapeutic Proteins to the Central Nervous System

  • Aaron J. RobinsonEmail author
  • Joy Rathjen
Chapter
Part of the Stem Cells and Cancer Stem Cells book series (STEM, volume 4)

Abstract

Pluripotent stem cells, including human embryonic stem cells and induced pluripotent stem cells, are defined by their ability to differentiate to form any of the cells of the embryo and mature organism, many of which can now be derived in vitro in response to defined factors. Pluripotence, coupled with the ability of these cells to be precisely genetically altered and expanded almost indefinitely, has led to much excitement about their prospects for use in cell transplantation therapies. Cell therapies will require an appropriate source of pluripotent cells that are amenable to expansion to therapeutically useful numbers and robust and reproducible protocols for differentiation of cells to a therapeutically useful phenotype. These protocols will need to involve appropriate quality control measures to ensure the resulting cell populations lack contaminating pluripotent (or other potentially tumorigenic) cells.

In this chapter, we describe the approaches we have used for generating mouse ES cell lines genetically modified to stably express a therapeutic transgene, and the differentiation protocol used to derive highly enriched populations of glial precursor cells from these cells. Discussion is included of some of the measures that have been taken to ensure the functional integrity of these manipulated cell lines is maintained, and the approaches used to determine the purity of the resultant cell populations. Although we have focused on this specific cell type we feel that the structure of this experimental approach could be applied more broadly to deriving other cell types from pluripotent cells.

Development of reproducible protocols for deriving glial precursor cells in large numbers and of high purity will allow further investigation of the specific host dependent and donor cell-dependent factors required for successful cell therapy approaches using various animal models of disease. A detailed understanding of these factors and adaptation of in vitro protocols to human pluripotent cells will ultimately be required for successful clinical translation of cell therapies.

Keywords

Pluripotent stem cells Differentiation protocol Glial precursor cell Transgenic protein Stem cell therapy Central nervous system disease 

Notes

Acknowledgments

The authors could like to thank Professor John Hopwood, Dr. Kim Hemsley and Professor Peter Rathjen for their support and guidance through the course of these studies. This work would not have been possible without the tireless efforts of Randall and Elizabeth Linton and the generous funding support of the Sanfilippo Children’s Research Foundation.

References

  1. Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, Zhang Y, Yang W, Gruber PJ, Epstein JA, Morrisey EE (2011) Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8(4):376–388PubMedCrossRefGoogle Scholar
  2. Crawley AC, Marshall N, Beard H, Hassiotis S, Walsh V, King B, Hucker N, Fuller M, Jolly RD, Hopwood JJ, Hemsley KM (2011) Enzyme replacement reduces neuropathology in MPSIIIA dogs. Neurobiol Dis 43(2):422–434Google Scholar
  3. Evans MJ, Kaufman MH (1981) Establishment in culture of pluripotential cells from mouse embryos. Nature 292(5819):154–156PubMedCrossRefGoogle Scholar
  4. Glaser T, Schmandt T, Brüstle O (2008) Generation and potential biomedical applications of embryonic stem cell-derived glial precursors. J Neurol Sci 265:47–58PubMedCrossRefGoogle Scholar
  5. Guan K, Chang H, Rolletschek A, Wobus AM (2001) Embryonic stem cell-derived neurogenesis. Retinoic acid induction and lineage selection of neuronal cells. Cell Tissue Res 305(2):171–176PubMedCrossRefGoogle Scholar
  6. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, Jaenisch R (2007) Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318(5858):1920–1923PubMedCrossRefGoogle Scholar
  7. Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, Yow A, Soldner F, Hockemeyer D, Hallett PJ, Osborn T, Jaenisch R, Isacson O (2010) Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA 107(36):15921–15926PubMedCrossRefGoogle Scholar
  8. Hovatta O, Jaconi M, Töhönen V, Béna F, Gimelli S, Bosman A, Holm F, Wyder S, Zdobnov EM, Irion O, Andrews PW, Antonarakis SE (2010) A teratocarcinoma-like human embryonic stem cell (hESC) line and four hESC lines reveal potentially oncogenic genomic changes. PLoS One 5(4):e10263PubMedCrossRefGoogle Scholar
  9. Hughes ED, Qu YY, Genik SJ, Lyons RH, Pacheco CD, Lieberman AP, Samuelson LC, Nasonkin IO, Camper SA, Van Keuren ML, Saunders TL (2007) Genetic variation in C57BL/6 ES cell lines and genetic instability in the Bruce4 C57BL/6 ES cell line. Mamm Genome 18:549–558PubMedCrossRefGoogle Scholar
  10. Hughes JN, Dodge N, Rathjen PD, Rathjen J (2009) A novel role for gamma-secretase in the formation of primitive streak-like intermediates from ES cells in culture. Stem Cells 27(12):2941–2951PubMedGoogle Scholar
  11. Keirstead HS, Nistor G, Bernal G, Totoiu M, Cloutier F, Sharp K, Steward O (2005) Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 25(19):4694–4705PubMedCrossRefGoogle Scholar
  12. Kim SU, Vellis J (2009) Stem cell-based therapy in neurological diseases: a review. J Neurosci Res 87(10):2183–2200PubMedCrossRefGoogle Scholar
  13. Lau AA, Hemsley KM, Meedeniya A, Hopwood JJ (2004) In vitro characterization of genetically modified embryonic stem cells as a therapy for murine mucopolysaccharidosis type IIIA. Mol Genet Metab 81:86–95PubMedCrossRefGoogle Scholar
  14. Lau AA, Hemsley KM, Meedeniya A, Robinson AJ, Hopwood JJ (2006) Directed differentiation and characterization of genetically modified embryonic stem cells for therapy. Methods Mol Biol 329:471–484PubMedGoogle Scholar
  15. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, Lynch C, Harness JV, Lee S, Barrero MJ, Ku S, Martynova M, Semechkin R, Galat V, Gottesfeld J, Izpisua Belmonte JC, Murry C, Keirstead HS, Park HS, Schmidt U, Laslett AL, Muller FJ, Nievergelt CM, Shamir R, Loring JF (2011) Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8(1):106–118PubMedCrossRefGoogle Scholar
  16. Lee JP, Jeyakumar M, Gonzalez R, Takahashi H, Lee PJ, Baek RC, Clark D, Rose H, Fu G, Clarke J, McKercher S, Meerloo J, Muller FJ, Park KI, Butters TD, Dwek RA, Schwartz P, Tong G, Wenger D, Lipton SA, Seyfried TN, Platt FM, Snyder EY (2007) Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 13(4):439–447PubMedCrossRefGoogle Scholar
  17. Martin GR (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 78(12):7634–7638PubMedCrossRefGoogle Scholar
  18. Ng ES, Davis RP, Azzola L, Stanley EG, Elefanty AG (2005) Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood 106(5):1601–1603PubMedCrossRefGoogle Scholar
  19. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S (2011) A more efficient method to generate integration-free human iPS cells. Nat Methods 8(5):409–412PubMedCrossRefGoogle Scholar
  20. Pera MF, Tam PP (2010) Extrinsic regulation of pluripotent stem cells. Nature 465(7299):713–720PubMedCrossRefGoogle Scholar
  21. Rathjen J, Rathjen PD (2003) Lineage specific differentiation of mouse ES cells: formation and differentiation of early primitive ectoderm-like (EPL) cells. Methods Enzymol 365:3–25PubMedGoogle Scholar
  22. Rathjen J, Lake JA, Bettess MD, Washington JM, Chapman G, Rathjen PD (1999) Formation of a primitive ectoderm like cell population, EPL cells, from ES cells in response to biologically derived factors. J Cell Sci 112:601–612PubMedGoogle Scholar
  23. Rathjen J, Haines BP, Hudson KM, Nesci A, Dunn S, Rathjen PD (2002) Directed differentiation of pluripotent cells to neural lineages: homogeneous formation and differentiation of a neurectoderm population. Development 129:2649–2661PubMedGoogle Scholar
  24. Rathjen J, Washington JM, Bettess MD, Rathjen PD (2003) Identification of a biological activity that supports maintenance and proliferation of pluripotent cells from the primitive ectoderm of the mouse. Biol Reprod 69(6):1863–1871PubMedCrossRefGoogle Scholar
  25. Robinson AJ, Crawley AC, Hopwood JJ (2005a) Over-expression of human lysosomal alpha-mannosidase in mouse embryonic stem cells. Mol Genet Metab 85:203–212PubMedCrossRefGoogle Scholar
  26. Robinson AJ, Meedeniya AC, Hemsley KM, Auclair D, Crawley AC, Hopwood JJ (2005b) Survival and engraftment of mouse embryonic stem cell-derived implants in the guinea pig brain. Neurosci Res 53(2):161–168PubMedCrossRefGoogle Scholar
  27. Robinson AJ, Zhao G, Rathjen J, Rathjen PD, Hutchinson RG, Eyre HJ, Hemsley KM, Hopwood JJ (2010) Embryonic stem cell-derived glial precursors as a vehicle for sulfamidase production in the MPS-IIIA mouse brain. Cell Transplant 19(8):985–998PubMedCrossRefGoogle Scholar
  28. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676PubMedCrossRefGoogle Scholar
  29. Tesar PJ, Chenoweth JG, Brook FA, Davies TJ, Evans EP, Mack DL, Gardner RL, McKay RD (2007) New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature 448:196–199PubMedCrossRefGoogle Scholar
  30. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145–1147PubMedCrossRefGoogle Scholar
  31. Tuleuova N, Lee JY, Lee J, Ramanculov E, Zern MA, Revzin A (2010) Using growth factor arrays and micropatterned co-cultures to induce hepatic differentiation of embryonic stem cells. Biomaterials 31(35):9221–9231PubMedCrossRefGoogle Scholar
  32. Vallier L, Mendjan S, Brown S, Chng Z, Teo A, Smithers LE, Trotter MW, Cho CH, Martinez A, Rugg-Gunn P, Brons G, Pedersen RA (2009) Activin/Nodal signalling maintainspluripotency by controlling Nanog expression. Development 136:1339–1349PubMedCrossRefGoogle Scholar
  33. Ware CB, Wang L, Mecham BH, Shen L, Nelson AM, Bar M, Lamba DA, Dauphin DS, Buckingham B, Askari B, Lim R, Tewari M, Gartler SM, Issa JP, Pavlidis P, Duan Z, Blau CA (2009) Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell 4:359–369PubMedCrossRefGoogle Scholar
  34. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R (2008) Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson’s disease. Proc Natl Acad Sci USA 105(15):5856–5861PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.Division of Molecular MedicineThe Walter and Eliza Hall Institute of Medical ResearchCarlton NorthAustralia
  2. 2.Menzies Research Institute TasmaniaUniversity of TasmaniaHobartAustralia

Personalised recommendations